Laura Orton

A virtual pharma company's products are made, tested, stored and monitored by partners. Here is where small teams should focus GxP audits, and how to prioritise on a limited budget.

The audit report behind a supplier approval is evidence your QP and an inspector may both rely on. Here is what UK pharma companies should check before appointing a GxP audit provider.

On-time closure doesn't mean the problem stopped. Learn why repeat deviations persist, what EU GMP expects from a CAPA system and how to design an effectiveness check that can fail.

The MHRA expects wholesale dealer's licence applicants to be inspection ready when they apply. Learn what has to be in place first, how long it takes and what the inspector will ask.

A change approved on site can still need a variation to the marketing authorisation. Learn how to connect change control to regulatory filings, and what the 2026 variations framework means for your process.

A current licence and a tidy data room don't show whether a quality system works in practice. Learn what quality due diligence tests, and which findings change price, terms and the first hundred days.

Learn how to diagnose pharmaceutical batch-review bottlenecks, protect QP capacity and recover backlogs without compromising compliance or supply. 

Learn how to assess pharmaceutical technology-transfer readiness across CMC, MS&T, Quality and Regulatory before validation and commercial supply. 

Learn how to build a risk-based pharmaceutical supplier qualification programme, identify hidden GxP risks and maintain effective ongoing supplier oversight. 

A complete-looking data room isn't the same as a sound CMC and regulatory position. Learn what a genuine review checks, and the red flags that most often reprice or derail pharma deals.

A strong scientific story doesn't guarantee commercial success. Learn what a proper commercial viability analysis tests, and where pharma business case assumptions usually break.

Built for You or Built to Buy? The licensed entity model you choose shapes your QMS, staffing and documentation from day one. Learn how to decide before you build, not after

Batch release delays rarely start on the production floor. Learn why review capacity, not manufacturing, is usually the real constraint, and what a structured review model does differently.

A big market opportunity isn't the same as being ready to enter it. Learn what a proper market entry readiness assessment covers, from regulatory pathway to supply chain, before you commit a launch date.

A QMS that only works on paper isn't a QMS. Learn what separates a compliant-looking quality system from one your team can actually follow under real operational pressure.

Guidelines change constantly, and regulatory teams fall behind quietly, one missed update at a time. Learn what a structured currency programme looks like and how to build one without adding headcount.

Generic GMP training gets people through the module. It doesn't get them through an inspection. See what role-specific training does differently, and why it matters when regulators start asking questions.

EU GMP Annex 19 has been rewritten. If you handle parallel-traded product, Section 9 now sets prescriptive retention-sample rules and a new digital-sample option, effective 24 September 2026. Here's what changed, what it means for your SOPs, and how to run the gap assessment before the deadline.

Recognise the signs of a manufacturing capability gap before it hits your timeline or submission. TDP's MS&T consultants explain how to diagnose, address, and get ahead of the problem.

Expanding into new markets without a dedicated regulatory affairs team is the reality for many pharma companies. Here is how to build and manage a global submission programme that holds up under agency scrutiny — from pathway strategy and dossier architecture to post-submission management.

Scale-up failures don't just delay manufacturing. They delay regulatory approval. Learn how proactive MS&T input protects your programme and strengthens your CMC package. 

Most regulatory submission delays trace back to CMC. Understand the most common gaps, why they happen, and how to prevent them before your filing reaches the agency. 

Need specialist CMC expertise but cannot justify permanent headcount? Learn how outsourced CMC models give growing pharmaceutical companies the capability they need, at the stages they need it most. 

Outsourcing regulatory affairs is not always the right call. But for many pharma businesses, it is. Here is how to know when the case stacks up

No quality team? No problem. Learn how scaling pharma companies build compliant, investor-ready quality functions without permanent headcount. Practical guidance from TDP.

No in-house audit team? Learn how to structure compliant GxP audit coverage using outsourced and retained models. Practical guidance for pharmaceutical and biotech organisations.

TDP's key takeaways from Making & Distributing Pharma 2026. What the MHRA said about AI governance, Annex 22, decentralised medicines, and the landmark transparency

Received an inspection finding from the MHRA or FDA? Learn how to triage, structure a credible CAPA response, and protect your programme timeline. Expert guidance from TDP.